Contribution to scale-up access to ART towards the 90/90/90 Targets

Robert Matiru,
HIV Portfolio Manager

WHO & UNAIDS Annual meeting with
Pharmaceutical Companies and Stakeholders
Geneva, 19-20 March 2015

The Task Ahead



Contents

1

UNITAID Strategy: 2013-2016

1

Simple, point of care (POC) diagnostics

2

Affordable, adapted pediatric medicine

3

Treatment of HIV/AIDS and co-infections

STRATEGY 2013-2016
Six Strategic Objectives

4

Treatment of malaria (ACT)

5

Treatment of second-line tuberculosis

6

Preventatives for HIV/AIDS, TB and malaria

UNITAID

UNITAID Model - Bringing innovation to reality

Innovation

PDPs | R&D | Pharma Industry | Tech Groups



UNITAID interventions

- Demonstration of proof of concept
- Reduction/ removal of regulatory barriers
- Introduction of better quality products
- Increase of competition in markets

Roll-out

Diagnostics | Medicines | Preventives | Systems

quality affordable effective commodites available faster

MOHs | GFATM | PEPFAR | PMI | DFID | Donors

UNITAID

2

Update on current UNITAID investments in HIV Diagnosis and Treatment

SO1: HIV Diagnostics

ACCESS	MARKET SHORTCOMINGS
• **CD4** testing: ~60% • **Viral load** (VL) testing: ~30% • **Early infant diagnosis** (EID): ~40%	**All products:** ↓ Information on quality; ↑ Burden of local approval ◔ **CD4:** few POC; ↑ Prices; ↓ Adaptability; ↓ Uptake ● **VL & EID:** no POC; ↓ Adaptability; ↑ Prices; ↓ Uptake
COMPONENT INTERVENTIONS	**IMPACT**
• **A:** Improve access, ↓ price to POC *(CHAI/UNICEF)*; Operational research in health systems *(MSF)*; Market Entry (*Developers*); Harmonized eval. protocols / (*LSHTM*) ; Open Polyvalent Platforms for VL (*FEI*); Self-testing (PSI) • **P:** ↓ barriers & prices for emerging tools; Streamline approval/procurement policies • **E:** Access to resistance testing; Improve rapid testing; Reduce IP barriers	• Diagnostics markets that makes available high quality, affordable, well-adapted diagnostics • 2-3 POCs for each test type, with price reduced up to 50% • Coverage increased by 25% for each test type

UNITAID

SO1: >US$ 200M in UNITAID investments for HIV POC Diagnostics: Policy development, Quality Assurance, Market Entry, Scale-up

World Health Organization

DxPQ $12.2M:
Quality Assurance

Elizabeth Glaser Pediatric AIDS Foundation

$63M for EID:
- Country preparation
- Scale-up

MEDECINS SANS FRONTIERES

$28.6M:
Demonstration projects and Op. Research

LONDON SCHOOL of HYGIENE &TROPICAL MEDICINE

$4.9M: Regulatory Harmonization

unicef

CLINTON HEALTH ACCESS INITIATIVE

$55M to date:
- Country preparation
- Scale-up
- Market intelligence
- Market/PH Impact

Market Entry

$20M:
Market competition

UNITAID

SO1: HIVST market intervention

Increased Access
Distribute low cost, quality-assured products
Optimised for safe scale-up & effective linkage into care & prevention
Both general and key populations

Informed demand
Define the best market strategies and packaging for HIVST
Based on consumer preferences, accuracy, uptake among target groups, and cost-effectiveness data

Strategic barriers
Support the full integration of HIVST into National policy & algorithms
Underpinned by WHO recommendations and guidelines
Inclusion of HIVST in global HIV planning and projection tools

Structural barriers
Encourage market entry and competition
Through estimation HIVST market size & growth projections
Support a harmonised regional regulatory approval framework

Country	# Tests Phase 1	# Tests Phase 2
Malawi	172,754	420,466
South Africa	0	36,000
Zambia	200,478	404,522
Zimbabwe	359,190	1,069,810
Total	**732,422**	**1,930,798**

psi Healthy lives. Measurable results.

UCL

LSTM LIVERPOOL SCHOOL OF TROPICAL MEDICINE

LONDON SCHOOL of HYGIENE &TROPICAL MEDICINE

UNITAID

SO2: HIV Paediatric Treatment

ACCESS	MARKET SHORTCOMINGS
• **Only 24% of children** in need of treatment were receiving ART at end of 2011 (compared to 35% of adults)	Few infant formulations (sprinkles); ↓ Adapted FDCs for regimens aligned with adult ART; ↑ Prices; Long lead times & other supply issues
COMPONENT INTERVENTIONS	**IMPACT**
• **A:** Development of child-friendly LPV/r-based FDCs & RTV *(DNDi);* Consolidate market/secure supply for paediatric ART; Expedite market entry of adapted paediatric combinations (CHAI IPMA)	• New adapted and affordable formulations in 2015 for WHO-recommended treatment for infants • Gains from UNITAID-CHAI engagement protected: continued affordable pricing, increased innovation and supply security

SO2: The Paediatric HIV Treatment Initiative (PHTI)



SO2: HIV Paediatric Treatment

Support to **DNDi** and **Cipla** to develop optimal treatments for children < 3 years (2013-2016)



SO3: HIV Treatment (all groups)

ACCESS	MARKET SHORTCOMINGS
• **9.7m** (35% of those eligible) on treatment at end of 2012 • **Additional 20m** must be enrolled by 2020 to meet 90:90:90 global targets	**All products:** ↓Availability of standardized, simplified, durable, less toxic regimens **First-line** ↑ Prices for improved regimens; Future API demand unclear **Second-line:** ↑ Prices; ↓FDCs; ↓ Uptake
COMPONENT INTERVENTIONS	**IMPACT**
• **A:** API market intelligence *(WDI)*; *Medicines Patent Pool*; Patent barriers *(Lawyer's Collective)* • **P:** Lower Prices/Increase access for 2L; Secure API supply; Expedite market entry/uptake of new, superior ART • **E:** Market information for improved forecasting	• Treatment markets that make available high quality, affordable, well-adapted products • Possible support for game changers: 1st-line ART for community-based programs and 2nd-line ART superior products • Opportunity for savings from supporting dose-reductions

SO3: MPP - Impact to date

Comparing actual costs & savings estimates

- ❑ MPP achieved payback point in 2H-2012
- ❑ Expectedly, after a lag of 18 months, savings began showing
- ❑ Gathering pace as licensees get approvals, sell in newer countries and compete
- ❑ 4.3 million patient-years supplied with TDF-formulations (Jan’12-Jun ‘14)
  - ✓ 119 countries so far
  - ✓ 31 new countries; 23 outside the territory
  - ✓ Notables in Q2-14: Brazil, Algeria
  - ✓ Some HICs too
- ❑ Total saving during Q1-12 to Q2-14 (2½ years): $41.7Mn
- ❑ Price drop in TDF - based formulations since the MPP’s agreement: 48-87%
- ❑ Updated figures will be available early 2015.



Thank you !

How to contact UNITAID:

Robert Matiru
HIV Portfolio Manager
matirur@unitaid.who.int

Smiljka de Lussigny
HIV Diagnostics Project Lead
delussignys@unitaid.who.int

Jane Galvao
HIV Treatment Project Lead
galvaoj@unitaid.who.int

Lorenzo Witherspoon
Senior Procurement Advisor
witherspoonl@unitaid.who.int

Carmen Perez-Cases
HIV Technical Officer, Market Dynamics
perezcasasc@unitaid.who.int